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Background: Many rapid nongenomic glucocorticoid 
actions are mediated by membrane-bound glucocorti-
coid receptors (GRs). S-palmitoylation is a lipid post-
translational modification that mediates the membrane 
localization of some steroid receptors. A highly ho-
mologous amino acid sequence (663YLCM 
KTLLL671) is present in the ligand-binding domain of 
hGRα, suggesting that hGRα might also undergo S-
palmitoylation. 
Aim: To investigate the role of the motif 
663YLCMKTLLL671 in membrane localization of the 
hGRα and in mediating rapid nongenomic glucocorti-
coid signaling.  
Methods and Results: We showed that the mutant re-
ceptors  hGRαY663A,  hGRαC665A and 
hGRαLL670/671AA, and the addition of the palmitoy-
lation inhibitor 2-bromopalmitate did not prevent 
membrane localization of hGRα and co-localization 
with caveolin-1, and did not influence the biphasic ac-
tivation of mitogen-activated protein kinase (MAPK) 
signaling pathway in the early time points. Finally, the 
hGRα was not shown to undergo S-palmitoylation. 
Conclusions: The motif 663YLCMKTLLL671 does 
not play a role in membrane localization of hGRα and 
does not mediate the nongenomic glucocorticoid ac-
tions. 
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The Role of S-Palmitoylation of the Human Glucocorticoid Receptor 
(hGR) in Mediating the Nongenomic Glucocorticoid Actions 
Introduction 
 
Glucocorticoids are steroid hormones that regulate a 
broad spectrum of physiologic functions essential for 
life, such as growth, reproduction, behavior, cognition, 
as well as many immune, metabolic and cardiovascular 
functions, through their ubiquitously expressed 
glucocorticoid receptor (hGR) (Charmandari et al. 
2005, Chrousos et al. 2004, Chrousos & Kino 2005, 
2007, Nicolaides et al. 2010, Rhen & Cidlowski 2005). 
The hGR belongs to the superfamily of steroid/thyroid/
retinoic acid receptor proteins that function as ligand-
dependent transcription factors. The hGR regulates the 
transcription rate of many genes either by direct 
binding to their promoter regions or through 
interactions with other transcription factors, such as 
nuclear factor (NF)-κB, signal transducers and 
activators of transcription (STATs) and activator 
protein (AP)-1 (Nicolaides et al. 2010, Rhen & 
Cidlowski 2005).  
 In addition to the genomic actions, 
glucocorticoids exert rapid, ‘non-genomic actions’, 
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which occur within seconds or minutes and are not 
inhibited by transcriptional and translational inhibitors 
(Ayroldi et al. 2012, Bellavance & Rivest 2012, Lee et 
al. 2012, Losel & Wehling 2003, Song & Buttgereit 
2006, Stellato 2004). Examples of non-genomic 
actions of glucocorticoids include i) the immediate 
suppression of ACTH secretion from the anterior 
pituitary gland following a rise in glucocorticoid 
concentrations (Hinz & Hirschelmann 2000); ii) the 
increased frequency of excitatory post-synaptic 
potentials in the hippocampus (Karst et al. 2005); the 
rapid and transient decrease in blood pressure 
associated with a concomitant increase in coronary and 
cerebral blood flow in patients with myocardial 
infarction or stroke (Hafezi-Moghadam et al. 2002); 
and some T cell-related immune functions (Löwenberg 
et al. 2006). These rapid non-genomic actions of 
glucocorticoids are likely to be mediated by membrane 
glucocorticoid receptors that transduce the 
glucocorticoid signal via activation of downstream 
kinases (Ayroldi et al. 2012, Bellavance & Rivest 
2012, Lee et al. 2012, Losel & Wehling 2003, Song & 
Buttgereit 2006, Stellato 2004). 
 Covalent lipid modifications anchor numerous 
signaling proteins to the cytoplasmic face of the 
plasma membrane (Linder & Deschenes 2007). S-
palmitoylation refers to a reversible thioster linkage of 
palmitate (a C16 saturated fatty acid) to cysteine (Cys) 
residues of soluble proteins with hydrophobic 
moieties. This post-translational modification is 
catalyzed by membrane-bound palmitoyl-transferases 
(PATs) and increases protein hydrophobicity, thereby 
enabling protein binding to membranes. Due to its 
reversible nature, this reaction provides a powerful on/
off  switch mechanism through anchoring/de-
anchoring of proteins on the plasma membrane (Linder 
& Deschenes 2007). 
 Many heptahelical G protein-coupled receptors 
(GPCR) contain a conserved F(X6)LL sequence, 
where X is any amino acid and L is leucine or 
isoleucine. F, LL, and the precise 6-amino acid spacing 
between F and LL are required for protein export from 
the endoplasmic reticulum (Duvernay et al. 2004). A 
similar to the F(X6)LL sequence, highly conserved, 9-
amino acid motif has been identified in the ligand-
binding domains (LBDs) of most steroid receptors, and 
in particular of the human estrogen receptors (ER) α 
and β, progesterone receptors A (PR-A) and B (PR-B), 
and the androgen receptor (AR). In contrast to typical 
GPCRs, the third amino acid of this motif 
(YLCMKTLL) in all steroid receptors except the 
mineralocorticoid receptor (MR) is cysteine. Recent 
studies have demonstrated that this motif plays an 
important role in S-palmitoylation, membrane 
localization and the steroid signaling through 
activation of the mitogen-activated protein kinase 
(MAPK) and phosphatidylinositol 3-kinase (PI3K) 
(Marino et al. 2006, Pedram et al. 2007). Mutation of 
the phenylalanine or tyrosine at position -2, cysteine at 
position 0, and hydrophobic isoleucine/leucine or 
leucine/leucine combinations at positions +5/6, relative 
to cysteine, significantly reduced membrane 
localization, MAPK and PI3K activation, thymidine 
incorporation into DNA and cell viability stimulated 
by specific steroid receptor ligands (Pedram et al. 
2007). The localization sequence mediated 
palmitoylation of some steroid receptors, which 
facilitated their caveolin-1 association, subsequent 
membrane localization, and nongenomic signaling by 
respective steroids. Therefore, S-palmitoylation within 
the LBD may be a crucial modification for membrane 
translocation and function of these steroid receptors 
(Pedram et al. 2007). 
 Intriguingly, in the LBD domain of the hGRα 
protein, a sequence highly homologous to the above-
discussed motif is present (663YLCMKTLL670), 
suggesting that hGRα might also undergo S-
palmitoylation (Marino & Ascenzi 2006). This post-
translational modification might account for 
membrane-initiated rapid nongenomic glucocorticoid 
signaling. The position of this motif in the crystal 
structure of the LBD of hGRα is shown in Figure 1. 
The hGRα sequence 663YLCMKTLL670 has been 
further confirmed to be palmitoylable by analysis with 
CSS-Palm (available from: http://bioinformatics.lcd-
ustc.org/css_palm/) (Marino & Ascenzi 2006). 
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Figure 1. Stereotactic conformation of the agonist form of 
the LBD of hGRα. The yellow arrow indicates the 9-amino 
acid sequence, 663YLCMKTLL670, which is located on 
helix 8. H: Helix 
 The aim of our study was to determine the role 
of the motif 663YLCMKTLLL671 in mediating rapid 
nongenomic glucocorticoid signaling and to 
investigate whether the hGRα undergoes S-
palmitoylation. We performed in vitro studies to 
determine the specific residues within the 9-amino acid 
motif of the LBD of hGRα that are crucial for rapid 
glucocorticoid signaling. Specifically, we investigated 
whether mutation of the amino acids Y, C and LL at 
positions -2, 0 and +5/6, respectively, relative to 
cysteine (C) in the 9-amino acid motif, significantly 
reduce localization of the receptor to the plasma 
membrane, palmitoylation, association with caveolin-
1, and MAPK and AKT activation. 
 
Materials and Methods 
 
Plasmids 
The pRShGRα plasmid expresses hGRα under the 
control of the Rous sarcoma virus (RSV) promoter. 
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Figure 2. (A-D) Localization of the wild-type hGRα (hGRαWT) or its mutant receptors expressed in COS-7 cells in the ab-
sence or presence of dexamethasone. (E) Localization of hGRαWT in the presence of the palmitoylation inhibitor. The localiza-
tion of hGRα-related proteins was examined with immunofluorescent staining. The yellow arrows point to membrane localiza-






The plasmids pRShGRαY663A, pRShGRαC665A and 
pRShGRαLL670/671AA were constructed by 
introducing the indicated mutations into the pRShGRα 
plasmid using PCR-assisted site-directed mutagenesis 
(Stratagene, La Jolla, CA, USA). The primers used for 
site-directed mutagenesis are shown in Table 1. The 
successful introduction of the indicated mutations into 
the pRShGRα plasmid was confirmed by sequencing. 
 
Cell cultures 
COS-7 embryonic African green monkey kidney cells, 
which do not express endogenously the glucocorticoid 
receptor, were grown in Dulbecco’s Modified Eagle 
Medium (DMEM) supplemented with 10% Fetal 
Bovine Serum (FBS) and penicillin-streptomycin. 
Cells were incubated in a humidified atmosphere of 





 COS-7 cells (3x105) were plated on glass 
coverslips in 6-well plates. Twenty-four hours later 
(confluency 90-95%), cells were transiently transfected 
with pRShGRα, pRShGRαC665A, pRShGRαY663A 
or pRShGRαLL670/671AA using lipofectamine 2000 
(Invitrogen, Carlsbad, CA, USA). Forty-eight hours 
after transfection, dexamethasone 10-6 M was added 
for 2 hours in specific wells. When indicated, the 
palmitoyl-acetyl-transferase inhibitor bromohexa-
decanoic acid (2-Br) (Sigma Aldrich, Gillingham, 
Dorset, UK) (100 μΜ, diluted in 100% DMSO) was 
added 30 min before dexamethasone administration. 
Subsequently, cells were washed with PBS, fixed with 
4% fresh paraformaldehyde in PBS for 10 min at room 
temperature, and permeabilized with 0.2% Triton-
Χ100 in PBS for 1 min. Prior to antibody incubation, 
cells were blocked with 2% BSA in PBS at room 
temperature. Following washing with PBS, cells were 
incubated with primary anti-hGRα antibody (dilution 
1:100 in 0.5% BSA-PBS) (polyclonal anti-rabbit 
immunoglobulin, Cat No. PA1-516, Thermo Fisher 
Scientific, Boston, MA, USA) for 2 hours and 
subsequently with secondary antibody (dilution 1:500 
in 0.5% BSA-PBS) (Alexa Fluor® 594 donkey anti-
rabbit IgG, Cat No A21207, Invitrogen) for 1 hour at 
room temperature. Cells were washed with PBS and 
samples were mounted in 4',6-diamidino-2-
phenylindole (DAPI) and stored at 4°C overnight. 
Samples were analyzed by confocal microscopy (DM 
IRB, Leica, Wetzlar, Germany). The confluency of the 
cells was 60-70% on each coverslip. 
 For double immunofluorescence staining, cells 
were co-incubated with 0.5% BSA-PBS containing a 
combination of primary anti-hGRα antibody (dilution 
1:100) (polyclonal anti-rabbit immunoglobulin, Cat 
No. PA1-516,  Thermo Fisher Scientific) and primary 
anti-caveolin-1 antibody (dilution 1:200) (monoclonal 
anti-mouse immunoglobulin, Cat No sc-53564, Santa 
Cruz Biotechnology, Santa Cruz, CA, USA) (placed 
directly on each coverslip) for 2 hours at room 
temperature. Following washing with PBS, cells were 
co-incubated with 0.5% BSA-PBS containing a 
combination of secondary antibodies (dilution 1:500 
each) (Alexa Fluor® 594 donkey anti-rabbit IgG, Cat 
No A21207, Invitrogen, and Fluorescein goat anti-
mouse IgG, Cat No F2761, Invitrogen) (placed directly 
on each coverslip) for 1 hour at room temperature. 
Samples were washed with PBS, mounted in DAPI 
and stored at 4°C overnight. Random fields of samples 
were selected, the cells with membrane localization of 
hGRα or co-localization of hGRα with caveolin-1 were 
counted manually, and the number of these cells was 
divided by the number of total cells within these fields. 
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Figure 3. Cytoplasmic, membrane and nuclear localization 
of the hGRα in the COS-7 cells expressing the wild-type 
hGRα (hGRαWT) or the mutant receptors. Amounts of 
hGRα-related proteins were examined in subcellular frac-
tionated samples with Western blotting. 
 Subcellular fractionation 
 COS-7 cells (2x106) were plated in 75-cm2 
flasks. Twenty-four hours later, cells were transiently 
transfected with pRShGRα, pRShGRαC665A, 
pRShGRαY663A or pRShGRαLL670/671AA using 
lipofectamine 2000 (Invitrogen). Forty-eight hours 
after transfection, cells were trypsinized and counted. 
From the total number of cells, 5x106 cells were 
washed once in PBS and were centrifuged (500 x g) 
for 3 min. PBS was carefully removed and cell pellets 
were mixed gently. The subcellular fractionation was 
performed using the Subcellular Protein Fractionation 
Kit (Pierce, Rockford, IL, USA) according to the 
instructions of the manufacturer. Equal amounts of 
protein (20 μg) were mixed with Laemli buffer (5X), 
heated at 95°C for 5 min and electrophoresed 
alongside molecular weight prestained marker (Page 
ruler ladder, Fermentas Inc, Burlington, Ontario, 
Canada) through an 8% SDS-PAGE gel for 1 hour. 
After electroblotting onto nitrocellulose membrane, 
proteins were incubated overnight at 4°C with 5% non-
fatty milk in TBS-Tween-20. Immunoblotting was 
performed for 2 hours at room temperature using 
mouse anti-GR antibody (2F8, Diagenode Inc, 
Denville, USA) (1:500, diluted in 5% non-fatty milk in 
TBS-Tween-20). After washing with TBS-Tween-20, 
the membrane was incubated with horseradish 
peroxidase-conjugated goat anti-mouse secondary 
antibody (Dako, Glostrup, Denmark) (1:5000, diluted 
in 5% non-fatty milk in TBS-Tween-20) for 1 hour at 
room temperature. Proteins were visualized using the 
ECL Plus Western Blotting Detection System 
(Amersham Biosciences, Little Chalfont 
Buckinghamshire, UK) and exposed to high 
performance chemiluminescence film (Kodak, 
Rochester, New York, USA). 
 
MAPK and AKT kinase assays  
 COS-7 cells (3x105) were plated in 6-well 
plates. Twenty-four hours later, cells were transiently 
transfected with pRShGRα, pRShGRαC665A, 
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Figure 4. Co-localization of hGRα and caveolin-1 in COS-7 
cells expressing (4A) the wild-type hGRα (hGRαWT) or 
(4B) its mutant receptors or the hGRαWT in the presence of 
2-Br. (4C) Addition of dexamethasone resulted in nuclear 




pRShGRαY663A or pRShGRαLL670/671AA using 
lipofectamine 2000 (Invitrogen), as described above. 
Twenty-four hours after transfection, the inhibitor 2-Br 
(100 μΜ diluted in 100% DMSO) was added in half of 
the wells. Sixteen hours later, cells were incubated 
with dexamethasone 10-6 M for different periods of 
time (0, 5, 10, 15, 30, 60 and 120 min). Cells were 
washed twice with PBS and lysed in 150 μl Complete 
Lysis-M (Roche, Basel, Switzerland) supplemented 
with Na2VO4 (0.2mM) and NaF (1mM). The 
homogenates were centrifuged (13,000 rpm at 4°C) for 
15 min to obtain whole cell extracts. Western blotting 
was performed using mouse anti-p-ERK antibody 
(Cell Signaling, Beverly, MA, USA) (1:1000, diluted 
in 5% non-fatty milk in TBS-Tween-20) or rabbit anti-
p-Akt antibody (Cell Signaling) (1:1000, diluted in 5% 
non-fatty milk in TBS-Tween-20) for 2 hours at room 
temperature. After stripping, the membrane was re-
blotted using rabbit anti-ERK antibody (Cell 
Signaling) (1:1000, diluted in 5% non-fatty milk in 
TBS-Tween-20) or rabbit anti-Akt antibody (Cell 
Signaling) (1:250, diluted in 5% non-fatty milk in TBS
-Tween-20) for 2 hours at room temperature. 
Following washing, the membrane was incubated with 
horseradish peroxidase-conjugated goat anti-rabbit 
secondary antibody (1:5000, diluted in 5% non-fatty 
milk in TBS-Tween-20, Dako) for 1 hour at room 




 COS-7 cells (5x106) were plated in 100-mm 
cell dishes. Twenty-four hours later, cells were 
transiently transfected with pRShGRα or erbA-1 using 
lipofectamine 2000 (Invitrogen). Forty-eight hours 
after transfection, supplemented DMEM was replaced 
by plain DMEM for 1 hour. Cells were then exposed to 
9,10-3H(N) palmitic acid (0,1 mCi/mL) and incubated 
for 2 hours at 37°C. Protein extracts were prepared as 
previously described, and protein concentrations were 
estimated with the Bradford protein assays. Equal 
amounts of protein extracts (500 μg) were used for 
immunoprecipitation assays. The anti-hGRα or anti-
caveolin-1 antibody was bound to magnetic beads for 
1 hour at 4°C. Protein extracts were then incubated 
with anti-hGRα- or anti-caveolin-1-bound magnetic 
beads overnight at 4°C. The next day the protein 
immunocomplex was washed six times, mixed with 
Laemli buffer (5X) and heated for 5 min at 95°C. 
Equal volumes of each sample were added to 4 ml 
scintillation fluid, and radioactivity was measured 
using a β-counter (Beckman LS6000IC counter, 
Beckman Coulter Inc., Fullerton, CA, USA). 
 
Statistical analysis   
 All experiments were performed at least three 
times. Statistical analyses were carried out using the 




Neither the mutant receptors nor the addition of 2-
Br prevented membrane localization of hGRα 
To examine the membrane localization of the hGRα, 
COS-7 cells were transiently transfected with 
pRShGRα, pRShGRαC665A, pRShGRαY663A or 
pRShGRαLL670/671AA, and the immunofluorescence 
microscopy analysis was performed. Membrane 
localization of the hGRα was observed in 15% of the 
cells transfected with pRShGRα (Figure 2A) and in 
13% of the cells transfected with pRShGRαC665A 
(Figure 2B), whereas the percentage of membrane 
localization of the hGRα in cells transfected with 
pRShGRαY663A or pRShGRαLL670/671AA was 
11% in each case (Figures 2C & 2D). Addition of the 
inhibitor 2-Br did not prevent the membrane 
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Figure 5. (A) Time-course effects of dexamethasone on the MAPK activity in COS-7 cells expressing the wild-type hGRα 
(hGRαWT) or its mutant receptors. (B) The effect of 2-Br on the MAPK activity in COS7 cells expressing the wild-type hGRα 
(hGRαWT) or its mutant receptors. Expression levels of total ERK and p-ERK were examined by Western blotting. 
(B) (A) 
localization in cells transfected either with the wild-
type or the mutant receptors (percentage of membrane 
localization 13%) (Figure 2E). Addition of 
dexamethasone resulted in nuclear translocation of the 
hGRα (wild-type or mutant hGRs) (percentage of 
membrane localization 0%) (Figures 2A-2D). Our 
immunofluorescence results were further confirmed by 
subcellular fractionation of COS-7 cells transfected 
with the pRShGRα or the mutant receptors (Figure 3). 
 
The wild-type hGRα co-localized with caveolin-1 at 
the plasma membrane 
We investigated whether the hGRα co-localizes with 
caveolin-1 using the double immunostaining method. 
Caveolin-1 was detected strongly as “dots” on the 
plasma membrane, as well as weakly in the cytoplasm 
in the COS-7 untransfected cells, suggesting a role of 
caveolin-1 in endocytosis/exocytosis processes. Co-
localization of the hGRα with caveolin-1 was observed 
at the plasma membrane of the COS-7 cells transiently 
transfected either with the hGRα or its mutants at the 
same percentages as above (Figures 4A & 4B). 
Addition of the inhibitor 2-Br did not prevent the co-
localization of hGRα with caveolin-1 (Figure 4B), 
whereas addition of dexamethasone resulted in nuclear 
translocation of hGRα without any co-migration with 
caveolin-1 (Figure 4C). 
 
The mutant receptors preserved their ability to 
induce rapid nongenomic glucocorticoid actions 
through MAPK activation 
To examine the role of the 663YLCMKTLLL671 
motif in the induction of rapid nongenomic 
glucocorticoid actions, kinase signaling assays were 
performed in COS-7 cells transiently transfected either 
with the pRShGRα or the mutant receptors. Addition 
of dexamethasone for different periods of time resulted 
in a biphasic activation of the MAPK activity through 
induction of ERK phosphorylation at 5 and 15 
minutes, either in the absence or presence of 2-Br 
(Figures 5A, 5B). All mutant receptors tested did not 
prevent this dexamethasone-induced biphasic MAPK 
activation; however the double-mutant receptor 
hGRαLL670/671AA activated this kinase pathway at 5 
and 10 minutes (Figures 5A, 5B). Interestingly, the 
activity of the AKT pathway was not induced by the 
dexamethasone-activated hGRα or the mutant 
receptors both in the absence or presence of the 
palmitoylation inhibitor (Figures 6A, 6B). 
 
The hGRα did not undergo S-palmitoylation 
To examine whether the hGRα was a palmitoylated 
protein, COS-7 cells transiently transfected with the 
pRShGRα or erbA-1 were incubated with 9,10-3H(N) 
palmitic acid. The immunoprecipitated caveolin-1 was 
used as positive control, whereas the empty vector was 
used as a negative control. Caveolin-1 was shown to 
incorporate 9,10-3H(N) palmitic acid, whereas the wild
-type hGRα did not incorporate the tritiated substrate, 
indicating that the hGRα did not undergo S-




In the present study, we investigated the role of the 
highly conserved motif 663YLCMKTLLL671 of the 
LBD of hGRα in mediating the rapid, nongenomic 
glucocorticoid actions. We demonstrated that this 9-
amino acid motif did not play a role in membrane 
localization of the hGRα and did not influence the co-
localization of the receptor with caveolin-1 or the 
ligand-induced activation of MAPK pathway. We also 
showed that the hGRα did not undergo S-
palmitoylation. 
 The 663YLCMKTLLL671 motif did not 
mediate the membrane localization of hGRα, granted 
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Figure 6. (A) Time-course effect of dexamethasone on the AKT activity in COS-7 cells expressing the wild-type hGRα 
(hGRαWT) or its mutant receptors. (B) The effect of 2-Br on the AKT activity in COS-7 cells expressing the wild-type hGRα 
(hGRαWT) or its mutant receptors. Expression levels of the total AKT and p-Akt were examined with Western blotting. 
that the mutant receptors pRShGRαC665A, 
pRShGRαY663A and pRShGRαLL670/671AA were 
localized at the plasma membrane in the same 
percentage compared to that of the wild-type hGRα. 
Moreover, this motif was not responsible for co-
localization of hGRα with caveolin-1. Indeed, in the 
absence of ligand, all the mutant receptors were still co
-localized with caveolin-1 at the membrane, while 
addition of dexamethasone triggered their nuclear 
translocation. Furthermore, the activation of MAPK 
signaling pathway was not influenced by the mutant 
receptors, while neither the wild-type receptor nor the 
mutant receptors activated the PI3K/AKT pathway in 
COS-7 cells. These findings clearly showed that the 9-
amino acid motif lying between amino acids 663 and 
671 of the hGRα LBD did not influence the membrane 
localization of the receptor or the MAPK-mediated 
nongenomic glucocorticoid signaling. 
 To examine whether the hGRα undergoes S-
palmitoylation by incorporating palmitic acid to the 
cysteine residue of the motif 663YLCMKTLLL671, 
we used the palmitoylation inhibitor 2-Br in some 
experiments and we performed palmitoylation assays 
using 9,10-3H(N) palmitic acid. The membrane 
localization of the receptor and the nongenomic 
glucocorticoid signaling were not affected by the 
presence of the inhibitor, suggesting that this lipid post
-translational modification did not play an important 
role for these actions. In addition, palmitoylation 
assays showed that compared with caveolin-1, which 
is a known palmitoylated protein, the hGRα did not 
incorporate palmitic acid. 
 We have chosen to investigate whether the 
663YLCMKTLLL671 was a palmitoylated motif, 
because this amino acid sequence was highly 
homologous to the conserved peptide located in the 
LBD of ERα and ERβ, PR-A and PR-B, and the AR. 
Pedram et al. (2007) demonstrated that these steroid 
receptors underwent S-palmitoylation through 
thioester linkage between palmitic acid and the 
cysteine residue located within the 9-amino acid motif. 
They showed that S-palmitoylation facilitated 
membrane localization, co-localization with caveolin-
1, thymidine incorporation into DNA, cell viability, 
and MAPK and PI3K activation. In subsequent studies, 
they demonstrated that heat shock protein 27 promoted 
S-palmitoylation of the above steroid receptors and 
was required for their membrane localization (Razandi 
et al. 2010). They also showed that DHHC-7 and -21 
were the specific PATs that catalyzed S-palmitoylation 
of ER, PR and AR (Pedram et al. 2012) and revealed 
the important role of estrogen membrane signaling in 
organ development and metabolism (Pedram et al. 
2013, 2014). Based on these findings, we hypothesized 
that the hGRα might be a palmitoylated protein 
mediating the rapid nongenomic glucocorticoid 
signaling. However, our results showed that the motif 
663YLCMKTLLL671 was not palmitoylated.  
 Our findings concur with two recent studies 
(Deng et al. 2015, Samarasinghe et al. 2011). In the 
latter study, Samarasinghe and colleagues (2011) 
investigated the role of nongenomic glucocorticoid 
actions in regulating the gap junction-mediated 
intercellular communication and neural progenitor cell 
proliferation. They demonstrated that a short time 
exposure of neural progenitor cells to dexamethasone 
reduced the gap junction-mediated intercellular 
communication through a signaling pathway initiated 
by membrane-bound glucocorticoid receptors, which 
co-localized with caveolin-1 and cellular Src (c-Src) 
kinase, and triggered a MAPK-mediated 
phosphorylation of connexin 43, an important gap 
junction protein (Samarasinghe et al. 2011). To 
examine whether this membrane localization of the 
receptor was palmitoylation-dependent, they expressed 
the hGRαC665A in CHO cells and found no difference 
in the number of cells with membrane localized hGRα, 
suggesting that the receptor might not undergo S-
palmitoylation (Samarasinghe et al. 2011). The second 
study by Deng et al. showed that the endogenously 
expressed GRα in 4B cells did not incorporate tritiated 
palmitic acid, indicating that the GRα did not undergo 
S-palmitoylation (Deng et al. 2015). Moreover, they 
showed that substitution of the highly conserved 
cysteine 683 to alanine preserved membrane 
localization of the receptor, suggesting that this amino 
acid did not play a role in the localization of the GRα 
at the plasma membrane (Deng et al. 2015). However, 
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Figure 7. Palmitoylation of wild-type hGRα and caveolin-1. 
Caveolin-1 incorporated 9,10-3H(N) palmitic acid, whereas 
the wild-type hGRα (hGRαWT) did not incorporate the triti-
ated substrate. Bars represent mean ± SEM of at least three 
independent experiments. **: P<0.01, n.s.: not significant, 
compared to control. 
they demonstrated that leucines located within this 9-
amino acid motif were essential for interaction with 
HSP90 and for ligand-binding, thereby influencing the 
transcriptional activity of the GR (Deng et al. 2015). 
Although this study showed for the first time that GR 
was not a palmitoylated protein, the authors did not 
further investigate the role of this 9-amino acid motif 
in nongenomic glucocorticoid actions. Our study 
shows that neither point mutations in this motif nor the 
addition of 2-Br influenced the biphasic activation of 
MAPK pathway, which is involved in mediating the 
nongenomic glucocorticoid effects. 
 Delineating the molecular mechanisms of 
nongenomic glucocorticoid actions is extremely 
important, because membrane-initiated glucocorticoid 
signaling pathways are implicated in several 
pathophysiologic mechanisms. Given that several 
cardioprotective and immunosuppressive actions of 
glucocorticoids are non-genomic (Hafezi-Moghadam 
et al. 2002, Löwenberg et al. 2006), it is likely that the 
development of specific agonists and antagonists with 
well-characterized effects, which are able to modify 
discrete glucocorticoid-induced cellular functions, will 
help significantly towards the therapeutic management 
of myocardial infarction, stroke and several 
immunological conditions. 
 In summary, we demonstrated that the 
663YLCMKTLLL671 did not play a role in membrane 
localization of the hGRα and did not influence the co-
localization of the receptor with caveolin-1 or the 
ligand-induced activation of the MAPK pathway. We 
also showed that the hGRα did not undergo S-
palmitoylation. The membrane localization of the 
receptor, as well as the molecular mechanisms 
underlying the nongenomic glucocorticoid actions still 
remain an enigma. Further studies are necessary to 
investigate these research questions and to explore 
their clinical implications.  
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